SEATTLE, March 21, 2019 /PRNewswire/ -- Viome, a
company transforming health through personalized nutrition based on
individual biology, today announces it will collaborate with
precision health leader, Helomics, to study the link between the
gut microbiome and ovarian cancer. The teams will begin with a
pilot study, which aims to reveal how different cancer treatments
impact the gut microbiome, and if the microbiome affects
effectiveness and toxicity of various cancer treatments. The hope
is to transform these findings into an innovative and holistic
approach to help oncologists better personalize ovarian cancer
therapy.
"We are excited to kick off this novel study to help the
millions of women suffering from ovarian cancer," says Naveen Jain, CEO and founder of Viome. "We
believe the outcome of our work will be revolutionary and will
offer powerful insights and effective treatments for patients."
The study will leverage Viome's proprietary microbiome analysis
platform and artificial intelligence (AI) platform. This will be
combined with Helomics' proprietary drug response and genomic
profiling of the patients' tumor, coupled with its AI-powered
bioinformatics platform, D-CHIP. The study will investigate if the
gut microbiome differs between ovarian cancer patients and those
without cancer.
"Helomics pioneered using knowledge gained from drug response
and genomic profiling of the patient's living tumor to help
individualize ovarian cancer therapy. The collaboration with Viome
is groundbreaking, generating data from the microbiome combined
with our existing data and using our respective AI platforms, to
offer an innovative, holistic and personalized approach to helping
oncologists choose the best treatment options for patients with
ovarian cancer," commented Gerald
Vardzel, President and CEO of Helomics Corporation.
Viome will also explore the role of nutrition and the gut
microbiome in ovarian cancer patients post-treatment in order to
develop personalized food recommendations to support and restore
the immune system, appetite, and sleep patterns often weakened by
cancer treatment.
Another goal of this research study is to demonstrate that
improving the gut microbiome through nutrition can play an
important role in taking a holistic approach to treating ovarian.
Results will be shared at the conclusion of the study.
About Viome: Viome is defining the future of health
through personalized nutrition based on individual biology. The
company uses advanced technology developed for National Security at
the Los Alamos National Lab to analyze all the genes expressed by
the gut microbiome to assess if the body is converting the foods we
consume into helpful nutrients or harmful toxins. Viome's
artificial intelligence platform transforms these powerful insights
into actions by delivering precise, personalized nutrition
recommendations for healthy living.
To learn more about Viome and its mission to make illness
optional, visit www.viome.com.
About Helomics:
Helomics is an artificial intelligence
and data driven Personalized Healthcare company located in
Pittsburgh, PA. Helomics
mission is to improve the standard of care for cancer patients
(especially gynecological) through innovative research and
development partnerships with pharmaceutical, diagnostic,
biotechnology, and academic organizations, leading to better and
more personalized treatments and diagnostic technologies for
cancer. Helomics' CLIA-certified lab provides clinical testing that
assists oncologists in individualizing patient treatment decisions,
by providing an evidence-based roadmap for therapy.
In addition to its proprietary precision oncology platform,
Helomics offers boutique CRO services that leverage its TruTumor™,
patient-derived tumor models coupled to a wide range of multi-omics
assays (genomics, proteomics and biochemical), and a proprietary
bioinformatics platform (D-CHIP) to provide a tailored solution to
our client's specific needs. The D-CHIP platform has been
developed through a joint venture with Skyline Medical Inc.,
producer of the FDA-approved STREAMWAY® System for automated,
direct-to-drain medical fluid disposal, to leverage the Helomics
D-CHIP™ platform to develop and market new approaches for
personalized cancer diagnosis and care.
For additional information, please visit www.Helomics.com.
About Precision Therapeutics Inc.
Precision
Therapeutics (NASDAQ:AIPT) operates in two business areas: first,
applying artificial intelligence to personalized medicine and drug
discovery to provide personalized medicine solutions for patients
and clinicians as well as clients in the pharmaceutical,
diagnostic, and biotech industries, and second, production of the
FDA-approved STREAMWAY® System for automated, direct-to-drain
medical fluid disposal. For additional information, please visit
www.precisiontherapeutics.com.
Precision Therapeutics' medicine business is committed to
improving the effectiveness of cancer therapy using the power of
artificial intelligence (AI) applied to rich data diseases
databases. This business has launched with Precision Therapeutics'
investment in Helomics Corporation. Helomics is 25% owned by
Precision Therapeutics.
Precision Therapeutics has also announced the formation of a
subsidiary, TumorGenesis to pursue a new rapid approach to growing
tumors in the laboratory, which essentially "fools" the cancer
cells into thinking they are still growing inside the
patient. Precision Therapeutics and Helomics have also
announced a proposed joint venture with GLG Pharma focused on using
their combined technologies to bring personalized medicines and
testing to ovarian and breast cancer patients, especially those who
present with ascites fluid (over one-third of patients). The growth
strategy in this business includes securing new partnerships and
considering acquisitions in the precision medicine space.
Sold through the Skyline Medical business of Precision
Therapeutics, The STREAMWAY System virtually eliminates staff
exposure to blood, irrigation fluid and other potentially
infectious fluids found in the healthcare environment.
Antiquated manual fluid handling methods that require hand carrying
and emptying filled fluid canisters present an exposure risk and
potential liability. Skyline Medical's STREAMWAY System fully
automates the collection, measurement, and disposal of waste fluids
and is designed to: 1) reduce overhead costs to hospitals and
surgical centers; 2) improve compliance with OSHA and other
regulatory agency safety guidelines; 3) improve efficiency in the
operating room, and radiology and endoscopy departments, thereby
leading to greater profitability; and 4) provide greater
environmental stewardship by helping to eliminate the approximately
50 million potentially disease-infected canisters that go into
landfills each year in the U.S. For additional information,
please visit www.skylinemedical.com.
Media Contact:
Factory PR
viome@factorypr.com
Investor Relations:
Bret
Shapiro, Managing Partner
CORE IR
(516) 222-2560
brets@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viome-and-helomics-partner-to-identify-personalized-treatment-for-ovarian-cancer-patients-300816258.html
SOURCE Viome